Melanie Börries

Current Position

Director of the Institute

Academic Education

2001 - 2005	Studies of Cell Biology, MD PhD Program at the University of Basel, Biozentrum, CH (PhD)
1994 - 2001	Studies of Human Medicine (M.D.), University of Lübeck

Advanced Qualifications

2005	Doctoral degree in Cell Biology (Dr. phil.), Biozentrum, University of Basel, CH
2004	Doctoral degree in Medicine (Dr. med.), University of Lübeck

Postgraduate Positions

2019 - present	W3-Professorship of Medical Bioinformatics at the University of Freiburg, Director of the Institute of Medical Bioinformatics and Systems Medicine, Medical Center - University of Freiburg
2013 - 2019	Group Leader at the DKTK/DKFZ Partner Site Freiburg, Institute of Molecular Medicine and Cell Research, University of Freiburg
2009 - 2012	FRIAS, Principal Investigator together with Hauke Busch (CCC Group), Institute for Advanced Studies-LIFENET, University of Freiburg
2005 - 2009	Postdoctoral Research Fellow, Institute of Experimental and Clinical Pharmacology and Toxicology, University of Freiburg
2001 - 2005	Assistant Physician, Department of Cardiology, Inselspital, University of Bern, CH (3 month/year, MDPhD program)

Link to all publications of Melanie Börries: PubMed

Publications on CRC 1453 funding

Salié H, Wischer L, D’Alessio A, …, Boerries M, …, Hofmann M, Thimme R, Pinato DJ, Longerich T, Bengsch B. Spatial single-cell profiling and neighbourhood analysis reveal the determinants of immune architecture connected to checkpoint inhibitor therapy outcome in hepatocellular carcinoma. Gut (2024). Grahammer F, Dumoulin B, Gulieva RE, Arnold F, …, Freedman BS, Busch H, Boerries M, Walz G, Huber TB. Cyclin-dependent kinase 4 drives cystic kidney disease in the absence of mTORC1 signaling activity. Kidney Int (2024). Talvard-Balland N, Braun LM, Dixon KO, …, Köttgen A, …, Börries M, …, Becher B, Köhler N, Wertheimer T, Kuchroo VK, Zeiser R. Oncogene induced TIM-3 ligand expression dictates susceptibility to anti-TIM-3 therapy in mice. J Clin Invest (2024). Moeed A, Thilmany N, Beck F, …, Börries M, …, Zanetta P, Schell C, Schwemmle M, Weber A, Häcker G. The Caspase-Activated DNase drives inflammation and contributes to defense against viral infection. Cell Death Differ (2024). Kessler S, Burke B, Andrieux G, …, Börries M, Rizzi M, Beer M, Schwemmle M, Reuther P, Schountz T, Ciminski K. Deciphering bat influenza H18N11 infection dynamics in male Jamaican fruit bats on a single-cell level. Nat Commun (2024). Vinnakota JM, Biavasco F, Schwabenland M, …, Börries M, …, Subklewe M, von Baumgarten L, Gill S, Prinz M, Zeiser R. Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome. Nat Cancer (2024). Czech M, Schneider S, Peltokangas N, …, Nachbaur D, Boerries M, Gerner RR, Grün D, Zeiser R. Lipocalin-2 expression identifies an intestinal regulatory neutrophil population during acute graft-versus-host disease. Sci Transl Med (2024). Weinelt N, Wächtershäuser KN, Celik G, Jeiler B, Gollin I, …, Börries M, Pampaloni F, van Wijk SJL. LUBAC-mediated M1 Ub regulates necroptosis by segregating the cellular distribution of active MLKL. Cell Death Dis (2024). Maas-Bauer, Stell AV, Yan KL, de Vega E, Vinnakota JM, …, Grosse R, …, Becher B, Börries M, Zeiser R. ROCK1/2 signaling contributes to corticosteroid-refractory acute graft-versus-host disease. Nat Commun (2024). Torella L, Klermund J, Bilbao-Arribas M, Tamayo I, Andrieux G, …, Börries M, Cathomen T, Zabaleta N, Gonzalez-Aseguinolaza G. Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1. EMBO Mol Med (2024). Wu Y, Zehnle PMA, Rajak J, Koleci N, Andrieux G, …, Börries M, Niemeyer CM, Flotho C, Bohler S, Erlacher M. BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia. Leukemia (2023). Ramamoorthy S, Lebrecht D, Schanze D, Schanze I, Wieland I, …, Börries M, Niemeyer CM, Zenker M, Flotho C. Biallelic inactivation of the NF1 tumour suppressor gene in juvenile myelomonocytic leukaemia: Genetic evidence of driver function and implications for diagnostic workup. Br J Haematol (2023). Apostolova P, Kreutmair S, Toffalori C, Punta M, Unger S, …, Börries M, …, Becher B, Vago L, Zeiser R. Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation – Immune signature correlates with response. Br J Haematol (2023). Andrieux G, Das T, Griffin M, Straehle J, Paine SML, Beck J, Börries M, Heiland DH, Smith SJ, Rahman R, Chakraborty S. Spatially resolved transcriptomic profiles reveal unique defining molecular features of infiltrative 5ALA-metabolizing cells associated with glioblastoma recurrence. Genome Med (2023). Lenz M, Eichler A, Kruse P, Galanis C, Kleidonas D, Andrieux G, Börries M, Jedlicka P, Müller UC, Deller T, Vlachos A. The amyloid precursor protein regulates synaptic transmission at medial perforant path synapses. J Neurosci (2023). Raute K, Strietz J, Parigiani MA, Andrieux G, Thomas OS, …, Börries M, Swamy M, Maurer J, Minguet S. Breast Cancer Stem Cell-Derived Tumors Escape from γδ T-cell Immunosurveillance In Vivo by Modulating γδ T-cell Ligands. Cancer Immunol Res (2023). Kleidonas D, Kirsch M, Andrieux G, Pfeifer D, Börries M, Vlachos A. Microglia modulate TNFα-mediated synaptic plasticity. Glia (2023). Greve G, Andrieux G, Schlosser P, Blagitko-Dorfs N, Rehmann UU, …, Hackanson B, Börries M, Lübbert M. In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts. Leukemia (2023). Isbell LK, Tschuch C, Doostkam S, Waldeck S, Andrieux G, …, Börries M, Illerhaus G, Duyster J, Schueler J, von Bubnoff N. Patient-derived xenograft mouse models to investigate tropism to the central nervous system and retina of primary and secondary central nervous system lymphoma. Neuropathol Appl Neurobiol (2023). Paul MC, Schneeweis C, Falcomatà C, Shan C, Rossmeisl D, …, Börries M, Rad R, Schneider G, Saur D. Non-canonical functions of SNAIL drive context-specific cancer progression. Nat Commun (2023). Thelen B, Schipperges V, Knörlein P, Hummel JF, Arnold F, …, Arnold SJ, Börries M, Tanriver Y. Eomes is sufficient to regulate IL-10 expression and cytotoxic effector molecules in murine CD4+ T cells. Front Immunol (2023). Antón-García P, Haghighi EB, Rose K, Vladimirov G, Börries M, Hecht A. TGFβ1-Induced EMT in the MCF10A Mammary Epithelial Cell Line Model Is Executed Independently of SNAIL1 and ZEB1 but Relies on JUNB-Coordinated Transcriptional Regulation. Cancers (2023). van Otterdijk SD, Klett H, Börries M, Michels KB. The impact of pre-pregnancy folic acid intake on placental DNA methylation in a fortified cohort. FASEB J (2023). Seidel P, Rubarth A, Zodel K, Peighambari A, Neumann F, …, Adlesic M, …, Schell C, Börries M, …, Follo M, Albers J, Frew IJ. ATR represents a therapeutic vulnerability in clear cell renal cell carcinoma. JCI Insight (2022). Rückert T, Andrieux G, Börries M, Hanke-Müller K, Woessner NM, …, Schell C, …, Duyster J, Zeiser R, Köhler N. Human β-defensin 2 ameliorates acute GVHD by limiting ileal neutrophil infiltration and restraining T cell receptor signaling. Sci Transl Med (2022). Corrales E, Levit-Zerdoun E, Metzger P, Mertes R, Lehmann A, Münch J, Lemke S, Kowar S, Börries M. PI3K/AKT signaling allows for MAPK/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanoma. Cell Commun Signal (2022). Ferrarese R, Izzo A, Andrieux G, Lagies S, Bartmuss JP, …, Kammerer B, Börries M, Carro MS. ZBTB18 inhibits SREBP-dependent lipid synthesis by halting CTBPs and LSD1 activity in glioblastoma. Life Sci Alliance (2022). Bauer J, Köhler N, Maringer Y, Bucher P, Bilich T, …, Börries M, …, Rammensee HG, Hailfinger S, Walz JS. The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma. Nat Commun (2022). Strohmeier V, Andrieux G, Unger S, Pascual-Reguant A, Klocperk A, …, Schell C, …, Börries M, Hasselblatt P, Warnatz K. Interferon-Driven Immune Dysregulation in Common Variable Immunodeficiency-Associated Villous Atrophy and Norovirus Infection. J Clin Immunol (2022). Chakraborty S, Andrieux G, Kastl P, Adlung L, Altamura S, …, Börries M, Busch H, Muckenthaler MU, Schilling M, Klingmüller U. Erythropoietin-driven dynamic proteome adaptations during erythropoiesis prevent iron overload in the developing embryo. Cell Rep (2022). Braig D, Runkel A, Eisenhardt AE, Schmid A, Zeller J, …, Kiefer J, Börries M, Eisenhardt SU. Individualized Mini-Panel Sequencing of ctDNA Allows Tumor Monitoring in Complex Karyotype Sarcomas. Int J Mol Sci (2022). Karlowitz R, Stanifer ML, Roedig J, Andrieux G, Bojkova D, …, Börries M, Cinatl Jr J, Boulant S, van Wijk SJL. USP22 controls type III interferon signaling and SARS-CoV-2 infection through activation of STING. Cell Death Dis (2022). Aktories P, Petry P, Glatz P, Andrieux G, Oschwald A, …, Börries M, Henneke P, Groß O, Prinz M, Kierdorf K. An improved organotypic cell culture system to study tissue-resident macrophages ex vivo. Cell Rep Methods (2022). Haring E, Andrieux G, Uhl FM, Krausz M, Prioretti M, …, Börries M, Aumann K, Zeiser R, Apostolova P. Therapeutic targeting of endoplasmic reticulum stress in acute graft- versus-host disease. Haematologica (2022). Hölzen L, Mitschke J, Schönichen C, Hess ME, Ehrenfeld S, Börries M, Miething C, Brummer T, Reinheckel T. RNA interference screens discover proteases as synthetic lethal partners of PI3K inhibition in breast cancer cells. Theranostics (2022). Devane J, Ott E, Olinger EG, Epting D, Decker E, …, Börries M, Metzger P, Schell C, …, Schlevogt B, Sayer JA, Bergmann C. Progressive liver, kidney, and heart degeneration in children and adults affected by TULP3 mutations. Am J Hum Genet (2022). Wanner N, Andrieux G, Badia-I-Mompel P, Edler C, Pfefferle S, …, Börries M, …, Scaturro P, Puelles VG, Huber TB.  Molecular consequences of SARS-CoV-2 liver tropism. Nat Metab (2022). Harder I, Münchhalfen M, Andrieux G, Börries M, Grimbacher B, …, Jellusova J, Warnatz K, Keller B. Dysregulated PI3K Signaling in B Cells of CVID Patients. Cells (2022). Flum M, Dicks S, Teng YH, Schrempp M, Nyström A, Börries M, Hecht A. Canonical TGFβ signaling induces collective invasion in colorectal carcinogenesis through a Snail1- and Zeb1-independent partial EMT. Oncogene (2022). Kind F, Fassbender TF, Andrieux G, Börries M, Meyer PT, Ruf J. Early PSA Change after [177Lu] PSMA-617 Radioligand Therapy as a Predicator of Biochemical Response and Overall Survival. Cancers (Basel) (2021). Corrales E, Levit-Zerdoun E, Metzger P, Kowar S, Ku M, Brummer T, Börries M. Dynamic transcriptome analysis reveals signatures of paradoxical effect of vemurafenib on human dermal fibroblasts. Cell Commun Signal (2021). Spohr C, Poggio T, Andrieux G, Schönberger K, Cabezas-Wallscheid N, Börries M, Halbach S, Illert AL, Brummer T. Gab2 deficiency prevents Flt3-ITD driven acute myeloid leukemia in vivo. Leukemia (2022). Frey P, Devisme A, Rose K, Schrempp M, Freihen V, Andrieux G, Börries M, Hecht A. SMAD4 mutations do not preclude epithelial-mesenchymal transition in colorectal cancer. Oncogene (2022). Sharma R, Sahoo SS, Honda M, Granger SL, Goodings C, …, Börries M, …, Erlacher M, Coulon S, Wlodarski MW. Gain-of-function mutations in RPA1 cause a syndrome with short telomeres and somatic genetic rescue. Blood (2022). Hoefflin R, Harlander S, Abhari BA, Peighambari A, Adlesic M, …, Börries M, Köttgen A, Heikenwalder M, Frew IJ. Therapeutic Effects of Inhibition of Sphingosine-1-Phosphate Signaling in HIF-2α Inhibitor-Resistant Clear Cell Renal Cell Carcinoma. Cancers (2021).